DUPHASTON

Opinions on drugs - Posted on Jul 16 2014

Reason for request

Reassessment of the Actual Benefit of all medicines indicated in hormone replacement therapy for the menopause at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code

Clinical Benefit

Substantial

The actual benefit of the proprietary medicinal product DUPHASTON remains substantial in the indication “Confirmed menopause (artificial cycle in combination with an oestrogen)” in non-hysterectomised postmenopausal women and within the limits defined for the use of the oestrogen treatment with which it is combined when the proprietary medicinal products are used in accordance with the recommendations of the Committee.

Therapeutic use